Sandra P. D'Angelo, MD
In an analysis of patient-reported outcomes (PROs) of the JAVELIN Merkel 200 trial (NCT02155647) of avelumab (Bavencio), investigators found that there was a similarity in proportion of responders with metastatic Merkel cell carcinoma based on clinical and PRO endpoints.1
Moreover, an additional analysis of this study showed that avelumab was a cost-effective end-of-life treatment option for patients with metastatic Merkel cell carcinoma compared with standard of care in the United Kingdom.2
JAVELIN Merkel 200 was the basis for the FDA’s accelerated approval of avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy.
... to read the full story